PMID- 28780634
OWN - NLM
STAT- MEDLINE
DCOM- 20180307
LR  - 20200306
IS  - 1534-6285 (Electronic)
IS  - 1527-2737 (Linking)
VI  - 18
IP  - 10
DP  - 2017 Oct
TI  - Holmium Laser Enucleation of the Prostate in Patients Requiring Anticoagulation.
PG  - 77
LID - 10.1007/s11934-017-0727-2 [doi]
AB  - PURPOSE OF REVIEW: This is to evaluate and discuss the literature surrounding 
      holmium laser enucleation of the prostate (HoLEP) in patients on anticoagulation. 
      RECENT FINDINGS: The relationship of benign prostatic hyperplasia (BPH) to 
      bothersome lower urinary tract symptoms (LUTS) is well established with a 
      majority of men over the age of 60 having significant symptoms. Patients with 
      severe enough symptoms often require surgery and with cardiovascular disease 
      ranking as the primary cause of death in the USA, a growing number will be taking 
      antiplatelet (AP) or anticoagulation (AC) for primary or secondary prevention of 
      disease. A review of the recent literature focusing on patients on AP/AC 
      undergoing HoLEP noted minimal adverse effects in the postoperative course aside 
      from prolonged bleeding requiring catheterization with continuous bladder 
      irrigation. Although patients with BPH and bothersome LUTS undergoing HoLEP are 
      at a slightly greater risk for prolonged bladder irrigation secondary to 
      bleeding, surgical outcomes are similar to men not on AP/AC. The literature 
      surrounding newer direct oral anticoagulants (DOACs) and HoLEP is limited, and 
      therefore, conclusions regarding continuation of DOACs cannot be drawn. However, 
      HoLEP appears to be a safe and effective procedure for BPH-related LUTS in 
      patients on AP/AC therapy.
FAU - Rivera, Marcelino
AU  - Rivera M
AD  - Indiana University School of Medicine, 1801 Senate Blvd. Suite 220, Indianapolis, 
      IN, 46202, USA.
FAU - Krambeck, Amy
AU  - Krambeck A
AD  - Indiana University School of Medicine, 1801 Senate Blvd. Suite 220, Indianapolis, 
      IN, 46202, USA.
FAU - Lingeman, James
AU  - Lingeman J
AD  - Indiana University School of Medicine, 1801 Senate Blvd. Suite 220, Indianapolis, 
      IN, 46202, USA. jlingeman@iuhealth.org.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Urol Rep
JT  - Current urology reports
JID - 100900943
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Cardiovascular Diseases/prevention & control
MH  - Humans
MH  - Laser Therapy/methods
MH  - Lasers, Solid-State/*therapeutic use
MH  - Lower Urinary Tract Symptoms/etiology/*surgery
MH  - Male
MH  - Platelet Aggregation Inhibitors/adverse effects/*therapeutic use
MH  - Postoperative Hemorrhage/*chemically induced
MH  - Prostatic Hyperplasia/complications/*surgery
OTO - NOTNLM
OT  - Anticoagulation
OT  - Benign prostatic obstruction
OT  - Holmium laser enucleation of the prostate (HoLEP)
OT  - Lower urinary tract symptoms
EDAT- 2017/08/07 06:00
MHDA- 2018/03/08 06:00
CRDT- 2017/08/07 06:00
PHST- 2017/08/07 06:00 [entrez]
PHST- 2017/08/07 06:00 [pubmed]
PHST- 2018/03/08 06:00 [medline]
AID - 10.1007/s11934-017-0727-2 [pii]
AID - 10.1007/s11934-017-0727-2 [doi]
PST - ppublish
SO  - Curr Urol Rep. 2017 Oct;18(10):77. doi: 10.1007/s11934-017-0727-2.